How are LBOs for companies trading at 30X EBITDA financed?

I work in the lower middle market space (commercial and industrials) where companies typically trade for 6-7x LTM EBITDA. These deals are typically financed with 3-4 turns of senior debt, a turn of mezz, and the rest funded via equity.

How are LBOs of tech or public companies that trade over 30x LTM EBITDA (e.g. Craft Brewers Alliance, $BREW) financed? Are unregulated credit funds like Golub anchoring these deals with a 15x unitranche solution? Even then the Sponsor has to cut a fat equity check.

 

I don't know anything about that company but think about the types of companies that trade for ridiculous multiples - it's usually fast growing and scalable companies. Now think about why you use some debt to finance buyouts sometimes - oftentimes it's to turbo charge the returns because you won't meet your cost of capital on an unlevered basis. But if your target co is growing at 20%+ annually with good runway, you might not need/want to use leverage at all.

 

Unlikely that Golub/a direct lender would provide 15 turns of leverage. Direct lenders are going to look at enterprise value and loan-to-value, but there are some limits to that. You may see a lot of tech deals trading at 12-15x being done with a 6-6.5x unitranche structure, and ~7 to 8 turns of leverage seems to be the upper limit for most middle market unitranche deals.

Echoing CHItizen's thoughts, I don't think many sponsors are acquiring performing assets at 30x EBITDA. Since Golub is primarily a sponsor-based lender, they likely aren't seeing many deals will EBITDA multiples in that range. Even high-growth middle market roll-up strategies, enterprise software companies, device manufacturers, etc. are typically trading hands at multiples below 15x.

 
Best Response

This will ultimately come down to the definition of Adjusted EBITDA. I believe you are looking at an unadjusted number, which will significantly skew the purchase multiple and leverage profile.

The Blue Nile deal was marketed at 4x leverage against an 11x purchase multiple. If you completely strip out add-backs, it looked more like a 9x deal against a 26x multiple:

https://www.ft.com/content/ce5d0eee-eea0-11e6-930f-061b01e23655

Lenders apparently believed that at least some portion of the EBITDA adjustments could be underwritten, and ultimately got comfortable with the deal. A large chunk of the add-backs were usual and customary (stock-based comp, removal of public company costs, etc.), and lenders likely gave some credence to at least part of the anticipated synergies.

While I think experienced creditors would haircut the synergies and not agree with the 4x marketed leverage, they probably aren't signing up for a 9x deal, either. Anecdotally, after looking at past filings and some of the customary add-backs, it is probably a 6-7x deal after credit is given to the usual and customary add-backs without giving much value to anticipated synergies.

 

I work for a firm in Europe which has a direct lending fund. I know that the team isn't even allowed to finance deals above a certain leverage due to limits imposed on them by the fund's bylaws. I know that some mid market direct lending funds in Europe are not allowed to go above either 7x or 8x net leverage. And most of these funds are starting to get uncomfortable when you are above 5x-6x net leverage in the lower mid market space. I am guessing funds in the US will have fairly similar restrictions.

At the end of the day, it depends on the deal. Even high growth deals of a great company with high cash conversion and favorable market dynamics most likely won't see a net leverage north of 8x in a mid market deal.

 

You are correct about the 6-7x ceiling the Fed placed on the banking system. This has driven the decline in leverage for bank-financed LBOs in recent years. The winners in this market have been the players in the shadow banking system (Crescent , Golub, etc.) as they don't have to follow the same leveraged lending guidelines. Similarly, Jefferies does not run a commercial bank so they are not bound by the max EBITDA restrictions that JPM is for example.

The restrictions set on banks paved the way for all these new unregulated direct lending platforms. They pop up on a weekly basis and the entrance of all these new credit funds with their billions of dollars of dry powder will continue to change the lending landscape. Assuming Trump doesn't dismantle Dodd Frank, it will be interesting to see how middle market companies are financed 5-10 years from now.

 

While there is no a legal/GAAP definition of EBITDA, bank examiners are definitely laser focused on EBITDA adjustments, because they realize that arrangers are using "large percentage" adjustments to lower the marketed leverage profile of a borrower. Deals that have adjustments accounting for more than 20% of EBITDA are increasingly drawing scrutiny, and regulators are likely to assess "real" leverage after stripping out all or some of the add-backs.

 

As a few others mentioned, it all comes down to adjustments that 'rationalize' leverage and PP metrics. I work in the space, and increasingly EBITDA for leverage purposes on larger deals has been composed of higher levels of adjustments (e.g., 30%+). As such, headline (unadjusted) multiples tend to look significantly higher than how the investors (equity and debt) view them.

 

Guys,

How about a PE case study where you get such a company - how legit is it to say that you gonna have 25% debt and 75% equity check? Is it even an LBO after that - there’s barely any leverage.

Let’s assume it’s a double digit growth company and it still spits out 25% IRR with that big equity check - would it work for the case study?

Thanks!

 

For a lot of those tech/SaaS deals where you see high leverage ratios, those deals are sometimes underwritten based on recurring revenue leverage rather than EBITDA leverage. These companies are trying to grow quick to be sold to another PE, VC firm or exited via IPO or other M&A and are spending a lot in marketing to gain more customers / gain market share so EBITDA wouldn’t be the best proxy for underwriting to these types of companies. These deals generally generate a higher return for investors. 

 

Qui quod omnis ad ut. Velit cum commodi et voluptas labore. Aut natus quis omnis at autem. Suscipit aut accusamus alias fuga pariatur.

Career Advancement Opportunities

April 2024 Private Equity

  • The Riverside Company 99.5%
  • Blackstone Group 99.0%
  • Warburg Pincus 98.4%
  • KKR (Kohlberg Kravis Roberts) 97.9%
  • Bain Capital 97.4%

Overall Employee Satisfaction

April 2024 Private Equity

  • The Riverside Company 99.5%
  • Blackstone Group 98.9%
  • KKR (Kohlberg Kravis Roberts) 98.4%
  • Ardian 97.9%
  • Bain Capital 97.4%

Professional Growth Opportunities

April 2024 Private Equity

  • The Riverside Company 99.5%
  • Bain Capital 99.0%
  • Blackstone Group 98.4%
  • Warburg Pincus 97.9%
  • Starwood Capital Group 97.4%

Total Avg Compensation

April 2024 Private Equity

  • Principal (9) $653
  • Director/MD (22) $569
  • Vice President (92) $362
  • 3rd+ Year Associate (91) $281
  • 2nd Year Associate (205) $268
  • 1st Year Associate (387) $229
  • 3rd+ Year Analyst (29) $154
  • 2nd Year Analyst (83) $134
  • 1st Year Analyst (246) $122
  • Intern/Summer Associate (32) $82
  • Intern/Summer Analyst (314) $59
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
Secyh62's picture
Secyh62
99.0
5
GameTheory's picture
GameTheory
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
kanon's picture
kanon
98.9
9
DrApeman's picture
DrApeman
98.8
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”